Is hyperhomocysteinemia a risk factor for osteoporosis?

Area of Science:

• Bone biology
• Metabolic disorders
• Biochemistry

Background:

• Hyperhomocysteinemia (HHCY) is a known risk factor for cardiovascular diseases (CVDs).
• Emerging evidence links HHCY to increased osteoporosis and fracture risk.
• The precise mechanisms by which HHCY affects bone metabolism require further elucidation.

Purpose of the Study:

• To investigate the impact of HHCY on bone metabolism and quality.
• To explore the potential role of HHCY in the pathogenesis of osteoporosis.
• To examine the effects of HCY on bone cells and extracellular matrix.

Main Methods:

• Analysis of clinical data on HHCY, fracture risk, and bone mineral density (BMD).
• Measurement of biochemical bone turnover markers.
• In vivo animal studies using hyperhomocysteinemic models.
• In vitro cell culture studies with varying HCY and vitamin B levels.

Main Results:

• HHCY is associated with increased fracture risk but minimal changes in BMD.
• Bone turnover markers indicate a shift towards increased bone resorption.
• Animal studies show reduced bone quality and stimulated resorption in HHCY.
• HCY accumulates in bone tissue, potentially via collagen binding.
• Cell studies reveal HCY stimulates osteoclasts, not osteoblasts, and disrupts collagen crosslinking.

Conclusions:

• HHCY adversely affects bone quality by stimulating bone resorption.
• Disturbance of collagen crosslinking by HCY contributes to bone fragility.
• HHCY, potentially exacerbated by vitamin B deficiencies, is causally linked to osteoporosis.